MIPLETAMIG
UNII DNP8BBW84R

Substance Identification & Data

This profile provides standardized clinical and technical data for Mipletamig, uniquely identified by the FDA Unique Ingredient Identifier (UNII) DNP8BBW84R.

Technical mappings include the Chemical Abstracts Service (CAS) Registry Number 2839556-21-5 and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.

FDA UNII Code

DNP8BBW84R

CAS Registry Number

2839556-21-5

RxNorm Concept ID

N/A

Detailed Substance Profile

Preferred Name

MIPLETAMIG

Official standardized name for this substance within the FDA UNII nomenclature system.

NCI Thesaurus

C157257

National Cancer Institute reference terminology for clinical and research data.

INN ID

12998

Sequential identifier assigned via the WHO International Nonproprietary Name program.

Substance Type

Mipletamig

ISO 11238 classification category (e.g., Chemical, Polymer, Protein).

Synonyms and Nomenclature

This section provides a complete list of nomenclature and identifier mappings for Mipletamig. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.

FDA Official Name

Mipletamig

Common Names & Synonyms

ANTI-CD123/CD3 BISPECIFIC ANTIBODY APVO436

IG chainscFvkh-G1hCH2CH3-scFvhk Homo sapiens and humanized (1-757) [scFvkh anti-IL3RA Homo sapiens (1-259) [V-KAPPA (Homo sapiens IGKV4-1*01 (99.0%) -IGKJ4*01 (100%), CDR-IMGT [12.3.10] (27-38.56-58.95-104)) (1-114) -20-mer tetrakis(tetraglycyl-seryl) linker (115-134) -VH (Homo sapiens IGHV3-23*01 (98.0%) -(IGHD) -IGHJ3*02 (100%), CDR-IMGT [8.8.17] (160-167.185-192.231-247)) (135-259)] -Homo sapiens IGHG1*01, G1m17,1CH3 D12, L14, G1v14-1 CH2 A1.3, A1.2, A1, G1v20 A105, G1v37 h S5 (hinge 1-15 C5>S (264) (260-274), CH2 L1.3>A (278), L1.2>A (279), G1>A (281), K105>A (366) (275-384), CH3 D12 (400), L14 (402) (385-489), CHS K2>del (490)) (260-490)] -18-mer (seryl-tris(glycyl-seryl)-prolyl-seryl) linker (491-508) -scFvhk anti-CD3E humanized (509-757) [VH (Homo sapiens IGHV1-69*02 (82.7%) -IGHD -IGHJ4*01 (92.9%), CDR-IMGT [8.8.14] (534-541.559-566.605-618)) (509-629) -20-mer tetrakis(tetraglycyl-seryl) linker (630-649) -V-KAPPA (Homo sapiens IGKV1-5*01 (81.5%) -IGKJ4*01 (100%), CDR-IMGT [5.3.9] (676-680.698-700.737-745)) (650-757)]]; dimer (270-270':273-273')-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, cell line CHO-K1, glycoform alfa

Immunoglobulin, anti-(human interleukin 3 receptor) (human-Mus musculus monoclonal APVO436 single-chain variable fragment VL-(GGGGS)4-VH) fusion protein with immunoglobulin G1 [5-serine,19-alanine,20-alanine,22-alanine,107-alanine,de-232-lysine] (human γ1-chain hinge region-CH2-CH3-domain) fusion protein with peptide linker [S(GGGGS)3PS] fusion protein with immunoglobulin anti-(human CD3 antigen ε-chain) (human-Mus musculus monoclonal APVO436 single-chain variable fragment VH-(GGGGS)4-VL), dimer

immunoglobulin IG chain scFvkh-G1hCH2CH3-scFvhk dimer bisdisulfide, anti-[Homo sapiens IL3RA (interleukin 3 receptor subunit alpha, interleukin 3 receptor alpha (low affinity), CD123)] and anti-[Homo sapiens CD3E (CD3 epsilon, Leu-4)], Homo sapiens and humanized monoclonal antibody, bispecific, tetravalent

mipletamig [INN]